Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/22/2008
 
First Published:
2/22/2008
1.
Phase I/II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following Chemoimmunotherapy Comprising Rituximab, Fludarabine, and Cyclophosphamide in Patients With CD20-Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
UMN-2007LS064
UMN-2007LS064, MT2007-12, UMN-0707M13561, NCT00625729
Last Modified:
5/6/2008
 
First Published:
4/2/2008
2.
Phase II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following a Preparative Regimen Comprising Cyclophosphamide and Fludarabine Phosphate in Patients With Recurrent and/or Metastatic Ovarian Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
UMN-2007LS138
UMN-2007LS138, UMN-MT2007-19R, UMN-WCC-53, UMN-0712M23462, NCT00652899
First Published:
12/23/2008
3.
Phase II Randomized Study of Intralesional Lymphokine-Activated Killer Cells Versus Polifeprosan 20 With Carmustine Implant (GliadelĀ® Wafer) as Consolidation Therapy After Primary Therapy in Patients With Newly Diagnosed Resectable Glioblastoma Multiforme
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
HOAG-HCC-08-01
HCC 08-01, NCT00814593
4.
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other
UARK 2003-18
NCT00089453
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute